AATF and Renal Protection

AATF 和肾脏保护

基本信息

  • 批准号:
    7766241
  • 负责人:
  • 金额:
    $ 27.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-04-01 至 2012-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Renal tubule epithelial cells are particularly vulnerable to ischemia/reperfusion (I/R)-induced injury. I/R is the most common cause of acute renal failure, a major clinical problem with exceptionally high morbidity and mortality. Although both apoptotic and necrotic cell death contribute renal I/R injury, effective treatment for this devastating condition is lacking. We have recently found that AATF (apoptosis antagonizing transcription factor) is expressed in renal proximal tubule cells wherein it plays a crucial role in inhibiting cell-death pathways in well-characterized models of renal I/R. Increased expression of AATF significantly ameliorated, while silencing of AATF by RNA interference (RNAi) exacerbated apoptotic and necrotic cell death following I/R in renal tubule epithelial cells. Preliminary studies indicates that AATF interacts with the proapoptotic protein Par-4 (prostate apoptosis response-4), and blocks cell death pathways initiated by Par-4 in renal tubule epithelial cells. Of importance, Par4-dependent cell death seems to be mediated by nuclear translocation and suppression of bcl-2 transcription. In addition, we found that AATF was novel phosphorylation substrate of Akt1, a protein kinase and an important downstream target of phosphatidylinositol 3-kinase. These findings open the exciting possibility that AATF represents a Par4- interacting, Akt1-regulated pathway that plays a critical role in controlling renal damage following I/R. We propose three specific aims to investigate this novel mechanism of renal protection: (1) to determine if AATF plays a critical role in protection of renal tubule epithelial cells, and if targeted delivery of AATF in the kidney using recombinant adeno-associated virus (AAV)-based vectors can be used as a potential therapeutic approach for I/R-induced renal injury in vivo; (2) to investigate the molecular mechanisms of Par4-mediaited renal toxicity and to study how transcriptional activation of the anti-apoptotic gene bcl-2 is regulated by AATF/Par-4 complex formation; and (3) to examine if binding and phosphorylation of AATF by Akt1 represents a novel regulatory mechanism underlying the renoprotective actions of AATF following I/R. Targeted delivery of AATF in the kidney by pharmacological and/or genetic manipulations may provide novel therapeutic applications for ischemia-reperfusion induced renal injury. PUBLIC HEALTH RELEVANCE Ischemia/reperfusion-induced renal injury (IRI) is the most common cause of acute renal failure, a major clinical problem with exceptionally high morbidity and mortality. Our preliminary studies suggest that AATF (apoptosis antagonizing transcription factor) is expressed in renal proximal tubule cells wherein it may play a crucial role in protecting against IRI. This project will use multidisciplinary approaches to examine the mechanisms underlying the renal protective actions of AATF at cellular and molecular levels, and to determine if pharmacological and/or genetic manipulations of renal AATF may provide new therapeutic applications for IRI.
描述(申请人提供):肾小管上皮细胞特别容易受到缺血/再灌注(I/R)诱导的损伤。I/R是急性肾功能衰竭最常见的原因,具有极高的发病率和死亡率,是一个主要的临床问题。尽管细胞凋亡和坏死性细胞死亡都会导致肾I/R损伤,但对这种破坏性的疾病缺乏有效的治疗方法。我们最近发现在肾I/R模型中,AATF(AATF)在肾小管上皮细胞中表达,在抑制细胞死亡途径中起关键作用。AATF表达的增加可显著改善I/R后肾小管上皮细胞的死亡,而RNA干扰(RNAi)沉默AATF则加剧了I/R后肾小管上皮细胞的凋亡和坏死细胞死亡。初步研究表明,AATF可与促凋亡蛋白PAR-4相互作用,阻断由PAR-4启动的肾小管上皮细胞死亡通路。重要的是,依赖PAR4的细胞死亡似乎是由核转位和bcl2转录抑制所介导的。此外,我们还发现AATF是Akt1的新的磷酸化底物,Akt1是一种蛋白激酶,也是磷脂酰肌醇3-激酶的重要下游靶点。这些发现开启了一种令人兴奋的可能性,即AATF代表了PAR4- AATF在肾小管上皮细胞的保护中发挥重要作用。我们提出了三个具体的研究目标:(1)确定AATF是否在肾小管上皮细胞保护中起关键作用,以及以重组腺相关病毒(AAV)为基础的载体介导的AATF是否可作为体内治疗I/R所致肾损伤的潜在途径;(2)探讨PAR4介导肾毒性的分子机制,并研究AATF/PAR-4复合体对抗细胞凋亡基因bcl2转录激活的调节作用;(3)研究AATF与Akt1的结合和磷酸化是否为AATF肾保护作用的一种新的调控机制。公共卫生相关性缺血/再灌注性肾损伤(IRI)是急性肾功能衰竭最常见的原因,具有极高的发病率和死亡率,是一个主要的临床问题。我们的初步研究表明,AATF(细胞凋亡拮抗转录因子)在肾脏近端小管细胞中表达,可能在保护肾小管缺血再灌注损伤中发挥重要作用。该项目将使用多学科方法在细胞和分子水平上研究AATF的肾脏保护作用的潜在机制,并确定肾脏AATF的药理和/或遗传操作是否可能为IRI提供新的治疗应用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

QING GUO其他文献

QING GUO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('QING GUO', 18)}}的其他基金

AATF and Renal Protection
AATF 和肾脏保护
  • 批准号:
    8021029
  • 财政年份:
    2008
  • 资助金额:
    $ 27.74万
  • 项目类别:
AATF and Renal Protection
AATF 和肾脏保护
  • 批准号:
    7581061
  • 财政年份:
    2008
  • 资助金额:
    $ 27.74万
  • 项目类别:
Regulation of APP Processing by Par-4
Par-4 对 APP 处理的规定
  • 批准号:
    6826810
  • 财政年份:
    2002
  • 资助金额:
    $ 27.74万
  • 项目类别:
Regulation of APP Processing by Par-4
Par-4 对 APP 处理的规定
  • 批准号:
    7152490
  • 财政年份:
    2002
  • 资助金额:
    $ 27.74万
  • 项目类别:
Regulation of APP Processing by Par-4
Par-4 对 APP 处理的规定
  • 批准号:
    6986751
  • 财政年份:
    2002
  • 资助金额:
    $ 27.74万
  • 项目类别:
Regulation of APP Processing by Par-4
Par-4 对 APP 处理的规定
  • 批准号:
    6574685
  • 财政年份:
    2002
  • 资助金额:
    $ 27.74万
  • 项目类别:
Regulation of APP Processing by Par-4
Par-4 对 APP 处理的规定
  • 批准号:
    6683219
  • 财政年份:
    2002
  • 资助金额:
    $ 27.74万
  • 项目类别:
Regulation of APP Processing by Par-4
Par-4 对 APP 处理的规定
  • 批准号:
    6767246
  • 财政年份:
    2002
  • 资助金额:
    $ 27.74万
  • 项目类别:

相似海外基金

AATF and Renal Protection
AATF 和肾脏保护
  • 批准号:
    8021029
  • 财政年份:
    2008
  • 资助金额:
    $ 27.74万
  • 项目类别:
AATF and Renal Protection
AATF 和肾脏保护
  • 批准号:
    7581061
  • 财政年份:
    2008
  • 资助金额:
    $ 27.74万
  • 项目类别:
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer
癌基因诱发的前列腺癌的进展机制
  • 批准号:
    7535750
  • 财政年份:
    1989
  • 资助金额:
    $ 27.74万
  • 项目类别:
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer
癌基因诱发的前列腺癌的进展机制
  • 批准号:
    8067808
  • 财政年份:
    1989
  • 资助金额:
    $ 27.74万
  • 项目类别:
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer
癌基因诱发的前列腺癌的进展机制
  • 批准号:
    7620985
  • 财政年份:
    1989
  • 资助金额:
    $ 27.74万
  • 项目类别:
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer
癌基因诱发的前列腺癌的进展机制
  • 批准号:
    7808835
  • 财政年份:
    1989
  • 资助金额:
    $ 27.74万
  • 项目类别:
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer
癌基因诱发的前列腺癌的进展机制
  • 批准号:
    7499091
  • 财政年份:
    1989
  • 资助金额:
    $ 27.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了